Circular RNA circRHOBTB3 inhibits ovarian cancer progression through PI3K/AKT signaling pathway

Yalan, Sun; Liu, Yanfang; He, Chen; Tan, Yujie

doi:10.23736/s0031-0808.20.03957-9

Cited by 29 publications

(8 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with the results reported by Deng's, Sun's and Wu's group, which indicated that hsa_circ_0007444 inhibited gastric cancer growth by sponging miR-654-3p (41) and ovarian cancer progression by sponging miR-570-3p and regulating the PTEN/PI3K/AKT signaling pathway (42,43), our study also demonstrated the tumor-suppressive function of hsa_circ_0007444 in ovarian cancer growth and metastasis both in vitro and in vivo. Both our study and Sun's group demonstrated that hsa_circ_0007444 could inhibit ovarian tumor growth in vivo.…”

Section: Discussionsupporting

confidence: 91%

Circular RNA hsa_circ_0007444 inhibits ovarian cancer progression through miR-23a-3p/DICER1axis

Zhang

Sun

et al. 2022

Preprint

View full text Add to dashboard Cite

Background Ovarian cancer is the leading cause of death in women with gynecological malignancy. Circular RNAs are a class of noncoding regulatory RNAs reported to be involved in cancer development and progression. Previous studies, including our own, have indicated that hsa_circ_0007444 is downregulated in ovarian cancer tissues. Our study aims to elucidate the function and mechanism of hsa_circ_0007444 in ovarian cancer progression. Methods The expression of hsa_circ_0007444 was determined by quantitative real-time PCR (qRT-PCR). Cell proliferation, invasion, migration and apoptosis were examined by cell counting-kit 8 (CCK-8), transwell, and flow cytometry assays. Tumor growth and metastasis were assessed in vivo using Balb/c nude mouse xenograft model and tail vein injection model. And the mechanism of action of hsa_circ_0007444 was analyzed by RNA-binding protein immunoprecipitation (RIP), luciferase reporter and rescue assays. Results Hsa_circ_0007444 was downregulated in ovarian cancer cell lines compared with normal ovarian epithelial cell line. Gain- and loss-of-function results indicated that hsa_circ_0007444 inhibited cell proliferation, invasion, migration and increased cell apoptosis of ovarian cancer cells in vitro and inhibited the tumor growth and lung metastasis in vivo. Additionally, the results of the bioinformatics analysis, and RIP, luciferase reporter and rescue assays confirmed that hsa_circ_0007444 can interact with AGO2 and sponge the microRNA miR-23a-3p, thereby upregulating DICER1 expression, which is an important tumor suppressor in ovarian cancer. Conclusions Hsa_circ_0007444 can inhibit ovarian cancer progression through the hsa_circ_0007444/miR-23a-3p/DICER1 axis.

show abstract

Section: Discussionsupporting

confidence: 91%

Circular RNA hsa_circ_0007444 inhibits ovarian cancer progression through miR-23a-3p/DICER1axis

Zhang

Sun

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Circ-ITCH was downregulated in OC and positively correlated with 5-years overall survival in OC patients ( Lin et al, 2020 ) while the overexpression significantly inhibited proliferation, invasion, glycolysis and promoted apoptosis in OC cells. Sun et al, demonstrated the downregulation of circ-RHOBTB3 in OC tissues and cells, and overexpression significantly inhibited cell proliferation, metastasis, and glycolysis ( Yalan et al, 2020 ). Circ-RHOBTB3 inhibited OC progression by inactivating the PI3K/AKT signaling pathway.…”

Section: The Regulatory Mechanism Of Ncrnas In the Glycolysis Of Ovar...mentioning

confidence: 99%

Noncoding RNAs in the Glycolysis of Ovarian Cancer

Zhang

Liu

2022

Front. Pharmacol.

View full text Add to dashboard Cite

Energy metabolism reprogramming is the characteristic feature of tumors. The tumorigenesis, metastasis, and drug resistance of ovarian cancer (OC) is dependent on energy metabolism. Even under adequate oxygen conditions, OC cells tend to convert glucose to lactate, and glycolysis can rapidly produce ATP to meet their metabolic energy needs. Non-coding RNAs (ncRNAs) interact directly with DNA, RNA, and proteins to function as an essential regulatory in gene expression and tumor pathology. Studies have shown that ncRNAs regulate the process of glycolysis by interacting with the predominant glycolysis enzyme and cellular signaling pathway, participating in tumorigenesis and progression. This review summarizes the mechanism of ncRNAs regulation in glycolysis in OC and investigates potential therapeutic targets.

show abstract

“… 113 Furthermore, circRNA RHOBTB3 (circRHOBTB3) overexpression significantly inhibited OC cell glycolysis. 121 So far, research on ncRNAs in metabolic regulation that contributes to OC progression is still very limited. The potential mechanisms of ncRNAs in OC metabolism need to be further explored, and investigating the role of ncRNAs in OC metabolism is a very important and promising area for developing novel OC therapy.…”

Section: Ncrnas As Therapeutic Targets For Oc Treatmentmentioning

confidence: 99%

“…78 , Lin et al113 (Continued)121 circ-CSPP1, circ-centrosome/spindle pole-associated protein; circ-ITCH, circRNA itchy E3 ubiquitin-protein ligase; circRHOBTB3, circular RNA RHOBTB3; DANCR, differentiation antagonizing non-protein coding RNA; ESRP1, epithelial splicing regulatory protein-1; FEN1, flap structurespecific endonuclease 1; FOXR2, forkhead box 2; GAS5, growth arrest-specific transcript 5; HOTTIP, lncRNA HOXA transcript at the distal tip; IL-6, interleukin 6; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; MICA/B, MHC class I chain-related molecules A/B; MMP, matrix metalloproteinases; ncRNA, non-coding RNA; NRCP, lncRNA ceruloplasmin; PARP1, poly (ADP-ribose) polymerase 1; PD-L1, programmed death-1 ligand 1; PFKFB2, fructose-2,6-biphosphatase 2; PTAR, lncRNA pro-transition associated RNA; SCAI, suppressor of cancer cell invasion; SDC, Syndecan; TP73-AS1, lncRNA P73 antisense RNA 1T; UCA1, urothelial carcinoma associated 1; VEGF, vascular endothelial growth factor; VEGFA, vascular endothelial growth factor A; ZEB1, zinc finger E-box binding homeobox 1.…”

mentioning

confidence: 99%

Recent advances of non-coding RNAs in ovarian cancer prognosis and therapeutics

et al. 2022

View full text Add to dashboard Cite

Ovarian cancer (OC) is the third most common gynecological malignancy with the highest mortality worldwide. OC is usually diagnosed at an advanced stage, and the standard treatment is surgery combined with platinum or paclitaxel chemotherapy. However, chemoresistance inevitably appears coupled with the easy recurrence and poor prognosis. Thus, early diagnosis, predicting prognosis, and reducing chemoresistance are of great significance for controlling the progression and improving treatment effects of OC. Recently, much insight has been gained into the non-coding RNA (ncRNA) that is employed for RNAs but does not encode a protein, and many types of ncRNAs have been characterized including long-chain non-coding RNAs, microRNAs, and circular RNAs. Accumulating evidence indicates these ncRNAs play very active roles in OC progression and metastasis. In this review, we briefly discuss the ncRNAs as biomarkers for OC prognosis. We focus on the recent advances of ncRNAs as therapeutic targets in preventing OC metastasis, chemoresistance, immune escape, and metabolism. The novel strategies for ncRNAs-targeted therapy are also exploited for improving the survival of OC patients.

show abstract

Circular RNA circRHOBTB3 inhibits ovarian cancer progression through PI3K/AKT signaling pathway

Cited by 29 publications

References 30 publications

Circular RNA hsa_circ_0007444 inhibits ovarian cancer progression through miR-23a-3p/DICER1axis

Circular RNA hsa_circ_0007444 inhibits ovarian cancer progression through miR-23a-3p/DICER1axis

Noncoding RNAs in the Glycolysis of Ovarian Cancer

Recent advances of non-coding RNAs in ovarian cancer prognosis and therapeutics

Contact Info

Product

Resources

About